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ABSTRACT 
Schizophrenia is a devastating psychiatric disorder that affects approximately 1% of the general 
population. Its complexity and enigmatic etiology place an economic and social burden on public 
health resources, while causing emotional distress for patients and their families. Twin, family, 
and adoption studies have shown evidence for a genetic component, but its complex pattern of 
inheritance has complicated the efforts for identifying susceptibility genes. The discovery of 
disease causing genes has public health relevance given that it could lead the path to pre-
symptomatic testing, preventative care, and a better prognosis. Recent studies have shown that 
inbreeding, through consanguineous marriages, is associated with increased risk for 
schizophrenia. In the genetically isolated island of Palau, the prevalence of schizophrenia is more 
than doubled at 2.7%. Here, we examine the role of excess homozygosity and regions of 
homozygosity-by-descent on schizophrenia risk in Palau. Palauans practice exogamy, but the 
likely limited size of the founding population, combined with recent population bottlenecks, 
ensures that homozygous segments of the genome, shared identical-by-descent from a common 
ancestor, occur regularly in Palauan genomes.  Five gene regions, RAB3GAP2, MARK1, DISC1, 
FAM184A, and IGSF9B were found to overlap segments that were commonly shared among 
subjects who were homozygous-by-descent. Cases and controls that were homozygous for these 
regions were counted and compared, with heightened representation from cases. Further SNP 
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haplotype and pedigree analysis, however, determined that none of the regions showed evidence 
of a highly penetrance recessive risk locus for schizophrenia.   
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1.0  INTRODUCTION 
Schizophrenia is a devastating complex psychiatric disease that affects approximately 1% 
of the general population. In the Palauan population, the occurrence of the disease is more than 
doubled (2.7%). It is possible this slight elevation is simply stochastic, but an intriguing 
possibility is that it has a biological origin. Palau, like many Oceanic populations has 
experienced a series of bottleneck events throughout its history. These, together with what was 
likely a small population size at founding, increases the genetic relationships among mating 
partners even in the face of the regular outbreeding practiced by Palauans. Given Palau’s 
geographical isolation and reduced gene flow, it could be an ideal candidate for gene mapping 
studies aimed to identify genes involved in conferring risk for schizophrenia. Perhaps cryptic 
inbreeding and its resultant impact on expression of recessive alleles could account for the 
increased rate of schizophrenia in Palau. Lu et al. (unpublished data) found that there is an 
association between diagnosis of schizophrenia in Palau and long chromosomal segments that 
are homozygous-by-descent. It is possible that homozygosity is associated with risk for 
schizophrenia, but the mechanism generating this association is not obvious, and specific gene 
regions harboring highly penetrant recessive alleles have yet to be identified.   
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2.0  BACKGROUND AND SIGNIFICANCE 
2.1 SCHIZOPHRENIA 
2.1.1 Epidemiology 
Schizophrenia is a complex psychiatric illness that presents similarly in all ethnic groups 
across the globe. It has consistently been shown to affect 1% of the world’s population, despite 
presenting among different cultures and in different environments (3, 6). Approximately 1 in 
10,000 individuals worldwide are newly diagnosed with schizophrenia each year (1). The onset 
of symptoms typically occurs between the ages of 16 and 30 years old, and although men and 
women can both be affected with the disease, men tend to experience symptoms at earlier ages 
(4). On average, the age of onset for men is during their early to mid 20’s, whereas women 
typically begin developing their first symptoms in their late 20’s (1). Studies have shown that 
prognosis of schizophrenia may be associated with a variety of factors. These factors include 
early age of onset, being male, having a lower level of education, and having pre-symptomatic 
adjustment issues (1). Females who show signs of the condition later in life tend to have a less 
severe prognosis.    
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2.1.2 Clinical Features of Schizophrenia 
Schizophrenia is identified by a constellation of many cognitive and emotional 
symptoms.  These symptoms can affect an individual’s logical thinking, speech, behavior, 
perception, motivations, and attention (1). The clinical manifestations of schizophrenia are 
categorized into two subsets: positive and negative symptoms.  
2.1.2.1 Positive Symptoms 
Positive symptoms represent features of schizophrenia that were not present in the 
individual prior to the onset of symptoms, and have an excess or distortion of normal functions 
(1). Potential examples of this subset of symptoms include delusions, hallucinations, 
disorganized speech, catatonic behavior, or inappropriate affect (2, 5). The DSM-IV defines 
delusions as “erroneous beliefs that usually involve a misinterpretation of perceptions or 
experiences” (1). The most common form of delusion is persecutory delusion in which the 
patient believes that harm will intentionally be placed on him or her by others.  Referential 
delusions are egocentric beliefs that external references, such as newspaper headings or song 
lyrics, are specifically aimed at the patient. Delusions are considered bizarre if they are 
completely implausible and are unable to be derived from reality (2). These thoughts are strongly 
retained by the individual despite evidence of the contrary. 
Hallucinations are sensory experiences that seem present to the affected individual, but 
are not justified by what is occurring in reality. Hallucinations can appear as auditory, visual, 
olfactory, gustatory, or tactile sensations (1). Auditory hallucinations are the most common form, 
which often include hearing voices in one’s head. This specific finding by itself is enough to 
confirm a diagnosis of schizophrenia.  
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Disorganization in thinking, speech, or behavior can present in a variety of ways. Those 
whose thinking is non-linear and unable to stay on-track often express this through their speech 
(1). Conversations consist of loose associations and may even be incomprehensible to the 
listener. Disorganized behavior can range from unusual agitation to complete impairment. Some 
individuals have shown the inability to maintain daily activities such as getting dressed or 
practicing hygiene. Other individuals appear to be completely unaware of their environment. 
Catatonic motor behaviors can occur when an individual loses all reactivity to their surroundings 
(1). A variety of motions can represent these behaviors, including remaining in a rigid posture 
even when intentionally moved, and becoming over stimulated and excited without reason (1). 
Although these symptoms are not necessarily specific to schizophrenia, their combined presence 
in an individual can aid in the attempt to determine a diagnosis.   
2.1.2.2 Negative Symptoms 
Negative symptoms appear when there is a loss or disruption in a behavior that was 
present prior to disease onset. Patients may experience a range of emotions or moods including 
alogia, affective flattening, avolition, or anhedonia. (5). Alogia includes loss of speech 
production, reflected in decreased verbal response and fluency (1). Affective flattening is 
reflected in an individual’s body language, and can include poor eye contact, immobility, and 
reduced facial expression (1). Avolition is characterized by the loss of motivation. It can often be 
seen in an individual who has stopped pursuing goal-oriented activities and who has lost interest 
in work or social activities (1). Anhedonia is not included in the definition of schizophrenia, but 
it is considered an associative feature. It is characterized by the inability to experience pleasure 
in activities and situations that were at one time pleasurable to the individual.  
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2.1.3 Diagnosis 
A patient is diagnosed with schizophrenia based on specific criteria that are outlined in 
the 1994 edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (1, 2). 
The requirements for diagnosis include specific symptomatic findings, duration, and exclusion of 
comparable psychiatric disorders (2).  Schizophrenia is diagnosed when there is a manifestation 
of at least two symptoms lasting the duration of six months, including one positive symptom 
lasting a minimum of one month (1). The presence of only one symptom may be sufficient for 
making a diagnosis if it represents a bizarre delusion or an auditory hallucination that consists of 
hearing non-existing voices (1).  
Symptoms associated with schizophrenia will often disturb levels of social functioning, 
affecting one’s ability to maintain a job, interact appropriately with others, and partake in self-
care practices. If the outcome of the symptoms do not affect the ability to function in society, it is 
unlikely to be diagnosed as a disorder. Similar symptoms are found in other psychiatric disorders 
including mood and schizo-affective disorders (2). These conditions, as well as other potential 
medical causes for the abnormal behaviors, must be excluded before a proper diagnosis of 
schizophrenia can be finalized. These disorders are likely to be ruled out if a patient does not 
show signs more highly associated with these conditions including major depression, manic, or 
mixed episodes (1). In addition, the use of certain drugs and medications that may be 
contributing to the development of symptoms must also be investigated and ruled out prior to a 
diagnosis (1).  
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2.1.4 Evidence for a Genetic Component 
Similar to other psychiatric disorders, identifying genes for schizophrenia has been 
complicated by its complexity. It is possible that its intricacies are a result of a range of factors 
including phenocopies, genetic heterogeneity, variable expression, polygenic inheritance, as well 
as environmental components (13). Despite the challenges, the evidence that schizophrenia is 
influenced by a genetic component continues to accumulate. Family, twin, and adoption studies 
provide evidence for a genetic component in schizophrenia.  
When genetics play a role in any condition, it is expected that the condition will occur 
more often among those related to affected individuals than those in the general population. 
There is an increase in the incidence of schizophrenia in family members of affected individuals, 
as well as a correlation in the level of risk with the degree of relation among members (6). As the 
portion of the genome that is shared identical-by-descent (IBD) increases, so does the risk for 
developing schizophrenia (7). Table 1 reports the values, reported by major European studies, for 
risk in reference to familial relationships (31).  Although these numbers vary by study, the 
direction of the pattern remains the same.  In general, the risk for schizophrenia in first degree 
relatives is 5-10 times greater compared to the risk in the general population (1, 7).  However, 
family studies cannot differentiate the environmental factors that are affecting risks as well.  
Twin studies provide evidence for the role of genetics in schizophrenia. A monozygotic 
twin of an affected individual is four times more likely to develop schizophrenia compared to a 
dizygotic twin (7). Both sets of twins share both pre and postnatal environments at the same 
level, yet monozygotic twins share complete genetic information, whereas dizygotic twins share, 
on average, only 50% of their genetic variation. Concordance rates for schizophrenia among 
identical twins have been reported to be between 50-57.7% and 12.8-15% for fraternal twins (6, 
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7).  Even in the situation where there is only one member of monozygotic twins affected with 
schizophrenia, the other twin is more likely to present with other disorders of psychosis or 
mental health issues (7). Based on twin studies, it is estimated that the heritability for 
schizophrenia is approximately 60-90% (3, 7, 11). Narrow-sense heritability is defined as “the 
proportion of phenotypic variance in a population attributable to additive genetic factors” (26).   
Adoption studies have the unique quality of being able to focus on biological risk for 
schizophrenia while removing the impact of postnatal environmental factors (1). Studies have 
shown that children adopted away from schizophrenic mothers are at a higher risk of developing 
the disease than children who were adopted away from unaffected mothers (7.7-11% compared 
to 0%) (7). This suggested that it is the biological, not the adoptive, relationship that is associated 
with familial transmission. Other studies went further to assess the risk to adopted paternal half 
siblings who shared biological fathers affected by the disease. Given that these half siblings did 
not share the same mother, they did not share the same prenatal environment. Since they were 
adopted, they also did not share the same postnatal environment. They only shared the genetic 
information passed from their mutual father. The results of these studies showed that adopted out 
half siblings who had shared a schizophrenic father were at greater risk of developing 
schizophrenia than adopted out half siblings who did not have a schizophrenic father, with 14 
half-siblings of affected cases developing schizophrenia compared to only two half-siblings of 
controls (32). This information continues to build on the idea that there is a genetic component 
involved in the risk for schizophrenia.  
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Table 1. Familial relationships and risk for schizophrenia (31) 
Relation Risk for schizophrenia 
Parents 4.4% 
Sibling (neither parent schizophrenic) 8.2% 
Sibling (one parent schizophrenic) 13.8% 
Fraternal twins of opposite sex 5.6% 
Fraternal twins of same sex 12.0% 
Identical twins 57.7% 
Children 12.3% 
Children (both parents schizophrenic) 36.6% 
Uncles/Aunts 2.0% 
Nephews/Nieces 2.2% 
Grandchildren 2.8% 
Half siblings 3.2% 
First cousins 2.9% 
General Population  0.86% 
 
2.2 PALAU 
2.2.1 Ethnography 
The Republic of Palau is an archipelago made up of over 200 islands that cover a 125 mile 
stretch (16). These islands are located in the westernmost part of Micronesia, far from any other 
major land mass. Settlement in the region began approximately 2,000 years ago, when migrants 
were believed to have come over from the Philippines or Indonesia, based on blood group 
clustering, linguistic analysis, and ethnographic studies. (15). Archeological studies have shown 
that the population has grown primarily in isolation from the point of the original settlement up 
until the last two centuries (9, 15). Throughout the history of Palau, a series of bottleneck events 
have taken place, resulting in the manipulation of its population size and dynamic. During World 
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War II, the population was reduced to only 3,500 natives. Today, it has grown to a population 
size of approximately 21,000 (16).  
Ethnographic characteristics of Palau led to geographic and genetic isolation. Through 
the generations, the cultural dynamic of Palau was made up of distinguished blood-based clans 
(9). Clans consisted of closely related families that were derived from a common female founder. 
The configuration of these clans has been continuously preserved by the maintenance of accurate 
records from excellent historians within the groups (15).  Despite practicing exogamy, genetic 
studies suggest that there are low levels of gene flow among the Palauans, likely due to a small 
founder population, several bottlenecks, and longstanding geographical isolation (27, 39). 
Limitations of the range of genetic heterogeneity have an effect on the genetic makeup of living 
Palauans, and may be contributing to increase risk of complex diseases among the population.  
2.2.2 Founder Effects 
Founder effects arise when the initial population of a geographic area is small and demographic 
growth occurs with limited migration (8). The small size of the population rapidly changes the 
frequency of any given allele over few generations, relative to a population with a larger 
effective population size. If one or more individuals in the founding population carried a genetic 
mutation associated with disease, the frequency of the mutation could increase rapidly in the 
population with each subsequent generation; alternatively, it could disappear from the population 
very rapidly. For the former to occur, reproductive abilities of carriers would have to remain 
intact. 
If the frequency of the mutation was truly increased, there would be a greater chance that 
matings between members of the population would produce offspring that were homozygous for 
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that specific mutation and it could lead to a greater frequency of disease. It has also been 
suggested that diseases that follow multifactorial inheritance may also be at higher frequencies in 
populations that have undergone founder effects.   
2.2.3 Schizophrenia in Palau  
In Palau, the prevalence of schizophrenia estimated to be 2.7%, which is more than 
double that of the worldwide estimates (9). This finding is not unique to Palau, in that many 
isolated island nations report increased frequency of schizophrenia, including 2.4% in North 
Sweden, and 3.2% in Finland (15). In Palau, the highest rates of schizophrenia occur among 
natives living in the western region of the islands, and the lowest prevalence occurs in the east. It 
is predicted that this may reflect the lack of genetic flow through the islands because of the 
mating practices set by the clans. In addition, the breeding of close relatives have been shown to 
be associated with an increased risk of several other complex diseases like schizophrenia, 
including diabetes, cancer, and heart disease (17). In several Middle Eastern countries, 
consanguineous marriages between first and second cousins are more likely to result in offspring 
with schizophrenia than in marriages between distantly related partners (17).  
Several studies have used the Palauan population in an attempt to discover genes and loci 
related to risk for schizophrenia. One study examined copy number variants (CNVs) that 
conferred risk for schizophrenia in subjects of European ancestry in Palauan subjects. Of the 
CNVs known or thought to convey risk for schizophrenia in other populations (18, 33), several 
were detected in the Palau sample, including 1q21.1, 15q11.2, 16p13.2, and Xp21.3 (18). It is 
believed that Palau’s small founder population, geographic isolation, history of bottleneck 
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events, and high prevalence of schizophrenia compared to the general population, makes the 
population an ideal candidate in the continuing search for the genetic etiology of schizophrenia.  
2.3 RISK LOCI IDENTIFIED OUTSIDE PALAU 
Many studies have investigated the molecular etiology of schizophrenia and related 
psychiatric disorders through genome-wide association studies in various populations. Mega-
analysis of genome-wide association studies found seven regions that were associated with 
increased risk for schizophrenia in individuals of European ancestry. These regions, including 
1p21.3, 2q32.3, 8p23.2, 8q21.3, 10q24.32-q24.33, 6p21.32-p22.1, and 18q21.2, were by using 
logistic regression of imputed “dosages” (fractional allocations of genotypes based on imputed 
genotype probabilities) against diagnostic phenotype (case/control status) (43). Region 6p21.32-
p22.1 maps to the major histocompatibility complex (MHC) which has previously been 
implicated in schizophrenia (43). The strongest signal that had not been described previously was 
found at region 1p21.3 (p=1.6x10-11). This region contains the primary transcript for MIR137. 
This gene is known as a regulator for adult neurogenesis and neuronal maturation (43). This 
finding paired with imaging studies that identified targets significant for association with 
schizophrenia suggest that MIR137-mediated dysregulation may be an etiologic mechanism in 
schizophrenia.  
By cross-disorder analyses, or meta-analyses involving schizophrenia, as well as other 
psychiatric conditions including autism spectrum disorders, attention deficit-hyperactivity 
disorder, bipolar disorder, and major depressive disorder, genome-wide association studies have 
identified additional regions that are associated with risk (40). These regions include 
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chromosome 2q32.1 which overlaps with gene ZNF804A,  an intronic SNP within gene ITIH3 on 
chromosome 3p21, an intron of gene AS3MT on chromosome 10q24, a region of chromosome 12 
within CACNA1C, and an intron of CACNB2 on chromosome 10 (40, 41, 43). Both CACNA1C 
and CACNB2 are genes highly expressed in the brain that encode L-type voltage-gated calcium 
channel subunits (40). Previous studies have identified CACNA1C as a susceptibility gene for 
schizophrenia, bipolar disorder, and major depressive disorder. Gain of function mutations in this 
gene are associated with a developmental disorder known as Timothy syndrome, which has 
autism as a major presenting feature (40). CACNB2 is an auxiliary voltage-gated calcium channel 
that is known to interact with CACNA1C to increase its function. Variants in this gene were 
found to be a main signal in bipolar disorder in affected individuals from the Han Chinese 
population (40). Significant association between these genes and the development of psychiatric 
disorders may suggest that voltage-gated calcium channel activity could be an important 
biological process in psychiatric disorders, including schizophrenia (40). Although not exclusive 
to schizophrenia, these findings could play a part in determining the molecular etiology that 
leads to a variety psychiatric diseases.   
Loci conveying risk for schizophrenia have also been found through the presence of rare 
copy number variants (CNV) at a particular region, especially those that cause the disruption of 
relevant genes. Many CNVs have been identified in samples of European ancestry that are 
believed to be associated with an increased risk for psychiatric conditions. For instance, deletions 
in the velocardiofacial syndrome region located on chromosome 22q11.2, are associated with a 
20 fold increased risk for psychiatric disorders, including but not limited to schizophrenia (18). 
Deletions and duplications between break points one and two of chromosome 15q11.2, known as 
the Prader-Willi/Angelman syndrome region have also been found to be associated with an 
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increase in risk. Additionally, large deletions have been identified that affect risk for 
schizophrenia on 1q21.1 and 15q13.3 (44), as well as CNVs that increase the risk for 
schizophrenia, autism, and other psychiatric disorders on 3q29, 16p11.2, and 17q12 (18).  
In addition to the effect that CNVs have on risk, another mechanism that has been found 
to increase risk of sporadic cases of schizophrenia in an Afrikaner population includes the 
presence of de novo mutations. 17.6% of sporadic cases were found to have de novo mutations, 
and 9.9% were found to have de novo CNVs (42). Exome sequencing was performed on cases 
and controls who did not have CNVs, in conjunction with parental studies. It was found that de 
novo variants were 3.7 times more likely to harbor nonsynonymous changes that increased the 
risk for schizophrenia compared to rare inherited changes (42). Four genes were identified as 
having higher rates of recurrent de novo mutations among cases compared to controls. These 
genes were DPYD, TRRAP, VPS39, and LAMA2. In addition, five genes were identified to be 
associated with risk for schizophrenia when altered by both de novo mutations and CNVs. These 
genes include DGCR2, TOP3B, CIT, STAG1, and SMAP2 (42). 
2.4 HOMOZYGOSITY-BY-DESCENT 
Homozygosity of alleles is more likely to occur when some form of inbreeding occurs. If 
we take the inbreeding level in the population as f, following traditional population genetics 
practice (30), and take the frequency of the rare allele as p, then the frequency of the 
homozygote, which under Hardy Weinberg equilibrium is p2, is increased to p2 + p(1-p)f. The 
impact, in terms of the approximate rate, is 1 + f/p. If p is small relative to f, homozygotes of the 
rare allele occur much more frequently then by chance and these homozygotes will tend to be 
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homozygous-by-descent (HBD). HBD is different from homozygosity per se because the 
variants, and typically the regions surrounding them, not only possess similar allele variants, but 
are actually identical alleles that came from the same founder. Recent literature has focused on 
individuals who inherit chromosomal segments with long stretches of consecutive homozygous 
SNPs, called runs of homozygosity (ROHs). Although all HBD subjects have regions with ROH, 
not all ROH are HBD. The rareness of having two chromosomes that share large segments of 
identical genetic information provides evidence that those two segments came from the same 
founder. Shorter segments that share identical information, which are rare in the population, also 
offers support that those segments are homozygous-by-descent.  
Studies have suggested that ROH (and, implicitly, HBD) is associated with risk for 
schizophrenia in certain samples (10, 11). However, the mechanism generating the association is 
not obvious and specific gene regions harboring highly penetrant recessive alleles have yet to be 
identified. According to a study done by Keller et al, a 0.01 increase in the amount of ROH 
segments within an individual’s genome can increase their risk for schizophrenia by 17% (11). 
When analyzing cases that had been diagnosed with schizophrenia versus unaffected controls, it 
was found that ROHs were more common among some of the affected cases (12). In 2011, a 
study was done to specifically analyze the association between the presence of homozygosity-by-
descent and the prevalence of schizophrenia in Palau. The study looked for statistically 
significant differences between the occurrence of HBD regions, the number of HBD regions, and 
the length of HBD regions among cases and controls. The results showed differences in the 
length of HBD regions, suggesting that cases possessed significantly longer HBD regions 
compared to controls (10).  
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No studies have determined whether or not HBD segments located at specific loci of any 
given chromosome increase the risk for schizophrenia. To investigate this question, we evaluated 
whether HBD regions show a pattern consistent with highly penetrant recessive risk alleles that 
are contained therein. If such regions could be found, they would provide a key step for 
determining risk alleles involved with schizophrenia.  
2.5 RELEVANCE TO GENETIC COUNSELING AND PUBLIC HEALTH  
Similar to other complex diseases, schizophrenia places a significant burden on health-
care resources. The estimated cost involved in the treatment and maintenance of schizophrenia is 
approximately $32.5 billion annually (20). This includes costs associated with morbidity, social 
disability, and associated substance abuse (29). By understanding the genetics of schizophrenia, 
it may be possible to understand its pathophysiology, leading to the development of more 
effective and cost reducing treatments (19). In addition, earlier detection of schizophrenia and 
treatment may alter and improve prognosis (19).   
Through the identification of susceptibility genes for schizophrenia, it would be possible 
to offer genetic testing to at risk individual. Identification of a susceptibility allele would lead to 
the initiation of preventative medicine, help identify early signs of disease onset, and would aid 
in determining which family members are also at risk.  Currently, the inheritance of 
schizophrenia  is considered to be complex and multifactorial (19). However, it is possible that 
other modes of transmissions can exist depending on the identified molecular etiology. Given 
what has been observed in Palau as well as in other isolated populations, it is possible that certain 
recessive alleles could be associated with risk for schizophrenia. Understanding the inheritance 
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of schizophrenia can allow for a better assessment of at risk individuals, and provide a better 
estimate of recurrence risk (21). Individuals who knew they were at risk could then take the steps 
to  consult with a psychiatrist to discuss signs of the disease and expectations regarding 
prognosis (19).  
Knowing that schizophrenia was a genetic condition not only put individuals in more 
control over their health care management, but it was also found to decrease stigma (21). 
Individuals may feel that a genetic attribution to schizophrenia moves the blame and 
responsibility of the disease away from the individual and onto the biological causes. Those who 
believed that schizophrenia was related to genetics were more likely to comply with 
pharmacological interventions and recommendations for hospitalizations (21). Part of this was 
because of the perception that a genetic illness is more serious and permanent, and thus required 
more attention. In a genetic counseling session, it is important to emphasize both genetic and 
environmental factors associated with the disease, as well as the psychosocial impacts that the 
disease can have on patients and their families.  
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3.0  MATERIALS AND METHODS 
3.1 SAMPLE AND GENOTYPING 
Continuing with the ongoing study of schizophrenia in Palau, DNA from blood samples 
of a total of 573 subjects were genotyped using Affymetrix Genomewide Human SNP Array 5.0, 
which include all known affected subjects (n=208, 36.3%), a sample of relatives of an affected 
(n=191, 33.3%), and control subjects (n=174, 30.4%). Research protocols and procedures were 
approved by institutional review boards (IRBs) at each of the sites in the US and the Republic of 
Palau. All subjects provided written informed consent to participate after receiving a full 
explanation of the study in both English and Palauan.  
Affected individuals were identified by medical records or referral by a family member, 
and confirmed using a modified version of the Schedule for Affective Disorders and 
Schizophrenia-Lifetime Version (SADS-L). Interviews were followed by intensive review of 
psychiatric medical records that described symptoms and treatment of the illness. The SADS-L 
interviews in combination with medical records helped determine whether a DSM-IV-based 
diagnosis of schizophrenia or a related psychotic disorder could be achieved. Subjects who did 
not meet criteria for schizophrenia or a related psychotic disorder (e.g., bipolar disorder, 
psychosis, schizoaffective) were excluded.  
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Controls were identified as subjects who had no history of psychiatric illness. In addition, 
controls had to be distantly related to the cases by at least three degrees. (Note that all individuals 
in Palau are likely to be related to some degree due to its isolated nature.)  
Quality control (QC) was conducted at the individual and SNP levels. At the individual 
level, samples were excluded if called genotypes fell below 96.2%; discrepancy between 
nominal and genetically-determined sex; or a large number of Mendelian errors (>20,000). SNPs 
were excluded if they were unmapped or monomorphic, had a call rate below 98.3% or more 
than 10 Mendelian errors. After this step, all SNPs passed a test for Hardy-Weinberg Equilibrium 
and there were 193 cases and 143 controls genotyped for 354,779 SNPs for analysis.  
3.2 IDENTIFYING ROH AND HBD SEGMENTS 
The analysis toolset PLINK was used to evaluate the presence of ROH, which required a 
minimum of 100 consecutive homozygous SNPs in order for a stretch to be classified as an ROH 
(28). The density specified is a minimum of 1 SNP per 50 kb, and there could not be a gap 
between SNPs that is greater than 2 Mb. To account for error, up to 2 missing genotypes were 
permissible (i.e., of 102 SNPs in a region, if 100 were homozygous and two interspersed SNPs 
had missing genotypes, this would be an ROH). We used Beagle to detect regions that are HBD 
(14). HBD regions were determined based on the rarity of the SNPs that compose a given ROH, 
and the likelihood that an individual could be homozygous for that particular haplotype had it not 
come from the same founder (14). A region is classified as HBD if, for each of the consecutive 
SNPs found therein, the probability that the SNP allele originated from a common ancestor 
exceeds 0.5. (14). The specific SNP range that the HBD region falls between is measured starting 
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with the first SNP in which an individual is determined to be HBD and continues along the 
haplotype until a SNP is reached that has an HBD probability of less than 0.5 (14). The subjects 
who had stretches that met these requirements were considered subjects with HBD regions.  
3.3 SEARCHING FOR PENETRANT RECESSIVE RISK ALLELES  
Previous analyses in the Palauan sample found individuals with schizophrenia to have 
greater total length of HBD compared to controls. However, whether or not these HBD regions 
harbor highly penetrant recessive alleles remains unclear. To investigate this further, we 
identified haplotypes within HBD regions that had the potential of being associated with risk for 
schizophrenia. Previous simulations showed that 3 or more subjects HBD at the same SNP 
would happen less than 5% of the time if HBD regions were randomly distributed across 
subjects’ genomes. Thus, we examined haplotypes in HBD regions where there were 3 or more 
cases sharing an HBD region. We evaluate overlap of HBD segments by dividing the region into 
different segments based on HBD sharing and count the number of cases and controls sharing 
each segment.  
Homozygosity for each SNP between cases and controls were compared using the 
Modified Quasi-likelihood Score test (MQLS) and a recessive mode of inheritance, with major 
and minor alleles specified as the recessive allele.  This testing provides an appropriate test of the 
null hypothesis or no association between homozygous SNP (segment) and schizophrenia risk, 
even when the sampled individuals are known to be related (22). Accounting for relatedness is 
important because in the Palau sample, genotypes will be more correlated among subjects due to 
shared ancestry. The relatedness of each subject that was homozygous for a particular segment 
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was determined with the use of genetic-based relationship matrices (Appendix A). Evaluation of 
haplotype structures was also performed by hand to evaluate patterns that would be difficult to 
capture by summary statistics such as those from MQLS. Final conclusions of the relationship 
between the haplotype stretches found in HBD regions and association with schizophrenia risk 
were a synthesis of calculations such as MQLS and careful inspection of patterns of haplotype 
sharing in pedigrees.    
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4.0  RESULTS 
4.1 IDENTIFYING HBD AND ROH SEGMENTS 
A total of 432 HBD regions were identified across the genome of the Palauan subjects. 
Approximately 54.8% of the subjects in Palau carried at least one HBD region, and 28% carried 
more than one HBD region. The average number of HBD regions per subject is 1.3 (±2.1) and 
the average length of an HBD region is 5.1Mb (±7.03). The smallest HBD region was 143.9 kb, 
and the largest HBD region was 78.4Mb. Subjects who had HBD regions had an average HBD 
length of 11.9 Mb (±19.9). Almost all subjects in the sample carried at least one ROH. The 
average number of ROH per subject was 72.6 (±20.56). The average length of an ROH in the 
subjects was 1.34Mb (±14.7Mb). The average cumulative length of ROH covered 3.5% of the 
genome at 100.5Mb (±40.81).  
While evaluating overlap of HBD segments among cases and controls, a significant trend 
favoring greater case representation was found relative to control representation in loci with 
higher numbers of HBD segments (Table 2). Cases and controls were also compared for relative 
homozygosity of each SNP using MQLS with recessive mode inheritance (Figures 1 and 2). In 
Figures 1 and 2, the top shows comparison of cases and controls on each SNP across the genome 
with regards to recessive inheritance of the major allele, and the bottom shows the comparison of 
cases and controls on SNPs in HBD regions shared by three or more cases. None of the SNPs 
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reached genome-wide significance. However, several regions were identified in which there was 
overlap among three or more affected subjects (Table 3). Although some subjects had HBD 
along the same region, they were not necessarily identical-by-descent to each other throughout 
the entire region. This meant that individually, they were all homozygous in the same region, but 
they were not all homozygous for the exact same haplotype variant.  
 
Table 2. Number of shared HBD regions in cases and controls 
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Figure 1. Comparison of cases vs. controls on homozygosity for SNPs using MQLS with recessive mode 
inheritance (major allele) 
Figure 2. Comparison of cases vs. controls on homozygosity for SNPs using MQLS with recessive mode 
inheritance (minor allele) 
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Table 3. HBD regions with 3 or more affected subjects 
Chromosome SNP Region Number of HBD subjects 
1 107519211-111117468 3 
1 206897233-222097120 4 
1 227316809-231762016 3 
3 8484476-13288817 3 
5 1514166-2622710 3 
6 106922247-124024764 3 
6 128753042-133915178 3 
7 792019-6151881 3 
7 9144986-10546273 3 
7 72951791-79981363 4 
8 3165317-6414803 2* 
9 3236490-5398357 4 
9 134128820-135954270 3 
10 15111853-21607729 3 
11 130376165-134443679 3 
12 25105886-33738526 4 
13 105576622-109061569 3 
14 80741858-83254290 4 
18 208084-2062155 3 
18 63511136-69498612 3 
20 5199068-12227537 4 
*although the HBD region on chromosome 8 only had two affected subjects that overlapped that region, it was
included in the analysis because both subjects were identical-by-descent through the entire region. This did not end
up being a significant finding.
4.2 SEARCHING FOR PENETRANT RECESSIVE RISK ALLELES 
Our strategy for identifying highly penetrant recessive risk alleles included examining the 
genotypes of affected sibling pairs, as well as cases and controls. Of the affected sibling pairs in 
our sample, there were three regions of the genome shared HBD, and one sibling pair had two of 
the HBD regions. We then evaluated other subjects, both affected and unaffected, to identify 
shared homozygous segments of these regions. At a minimum, we considered sub-haplotypes of 
the original HBD haplotype of at least length 10 SNPs. Upon evaluating these regions for 
additional subjects who share such haplotype (Table 4) one haplotype consisting of 34 SNPs 
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(chromosome 2: 187,577,486-187,986,279) was shared by an additional 18 cases and 5 controls, 
giving an odds ratio of 2.87. 
Although the odds ratio does not lend much support to the possibility of a highly 
penetrant recessive risk allele in the region, we investigated this issue further by looking at 
extended haplotypes of these 18 cases and 5 controls (chr2: 186,973,280-188,261,318) (Figure 
3).  Several haplotypes were identified and labeled A, B, D, and E. We labeled the shared 
haplotype between the siblings sharing the region HBD, as haplotype H. Two additional pairs of 
siblings in separate nuclear families, were determined to be homozygous for haplotypes A and B, 
and were assumed to be identical-by-descent. Additional identified haplotype variants had slight 
differences compared to these haplotypes, which we label as A’, A”, H’, D, E, and E’.  
Table 4. Homozygous haplotypes shared with siblings with HBD sharing 
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We examined haplotypes for family members of affected and control individuals and 
found the distribution of these haplotypes in families not to be consistent with the segregation of 
a penetrant recessive risk variant. We present in Figure 3 the pedigrees and haplotype sharing for 
the three nuclear families with pairs of siblings sharing homozygous haplotypes assumed to be 
identical-by-descent. In Family 1, the affected siblings (20306, 22354) are homozygous for H. In 
Family 2, the affected siblings (25057, 20302) are homozygous for B. In family 3, the affected 
siblings (20330, 20310) are homozygous for A. In Family 2, there are two additional siblings 
(25071, 25073) that are unaffected, yet homozygous for B similar to their affected siblings. In 
Family 3, there are two affected siblings (13872, 20256) that are heterozygous for A. Based on 
haplotype structure, haplotypes A and B show 67% and 86% similarity with haplotype H, which 
is a portion of the original HBD segment. Thus, there was no consistent pattern that offered 
support that there was association between the haplotypes and disease status.   
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Table 4. Continued
Figure 3. Family pedigrees of affected siblings with shared HBD regions 
Symbols without subject ID numbers did not have genotyping information 
In addition to examining HBD regions shared by siblings, sub-haplotypes within the 
larger HBD haplotypes shared by three or more cases were evaluated. Evaluation of sub-
haplotypes amongst additional cases and controls revealed some sub-haploptypes that were 
overrepresented in cases, relative to controls. Five particular sub-haplotypes were evaluated to 
identify if any were potentially harboring recessive risk alleles. These regions overlapped with 
genes RAB3GAP2, MARK1, DISC1, FAM184A, and IGSF9B. RAB3GAP2 had previously been 
implicated in autosomal recessive diseases (24), and MARK1 and DISC1 had previously been 
associated in risk for autism and schizophrenia (23, 25). This information is summarized in 
Tables 5 and 6. 
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Table 5. Summary of Cases and Controls who are homozygous for the haplotype 
Chromosome HBD 
region 
SNP 
stretch 
Gene Cases 
Homozygous 
for 
Haplotype 
Controls 
Homozygous 
for 
Haplotype 
Odds 
Ratio 
1 206897233-
222097120 
218368739-
218511547 
RAB3GAP2* 14 8 1.3296 
1 206897233-
222097120 
218579529-
218906324 
MARK1** 9 3 2.2989 
1 227316809-
230388213 
230223388-
230384737 
DISC1*** 7 2 2.6720 
6 106922247-
124024764 
118587907-
119427882 
FAM184A 7 1 5.3817 
11 130376165-
134443679 
133954456-
134090010 
IGSF9B 14 7 1.5307 
*Previously implicated in autosomal recessive disease
**Previously implicated in autism 
***Previously implicated in schizophrenia 
Table 6. Summary of Cases and Controls with one copy of the haplotype 
Chromosome HBD 
region 
SNP 
stretch 
Gene Cases with 
one copy of 
the 
Haplotype 
Controls 
with one 
copy of the 
Haplotype 
Odds 
Ratio 
1 206897233-
222097120 
218368739-
218511547 
RAB3GAP2 91 70 0.9431 
1 206897233-
222097120 
218579529-
218906324 
MARK1 62 39 1.2742 
1 227316809-
230388213 
230223388-
230384737 
DISC1 53 37 1.0948 
6 106922247-
124024764 
118587907-
119427882 
FAM184A 50 36 1.0490 
11 130376165-
134443679 
133954456-
134090010 
IGSF9B 84 52 0.9391 
4.2.1 RAB3GAP2 Region 
Four affected subjects shared a locus HBD on 1q41 comprised of 1,695 SNPs spanning 
206,897,233 bp to 222,097,120 bp (Build HG 18). None of these subjects, however, share a 
substantial portion of their haplotypes. The largest portion of the locus shared among three of the 
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subjects is an 11 SNP sub-haplotype (218,368,739 bp to 218,511,547 bp). (Figure 4-A)  This 
sub-haplotype falls within the RAB3GAP2 gene. For this sub-haplotype, we identified 14 cases 
and 8 controls that were also homozygous and yielding an odds ratio of 1.33.  
The odds ratio does not lend much support for a highly penetrant recessive risk allele in 
this region. Thus, it is possible that sharing of this 11 SNP sub-haplotype could have been due to 
a risk allele with a different inheritance pattern, such as an additive effect on risk. To evaluate 
this possibility, we looked through all variants of the haplotype located at this 11 SNP locus that 
were carried by cases. Two variants of the haplotype (Figure 5) were found in homozygous or 
compound heterozygous cases. Cases were either homozygous for one of the variants, or 
compound heterozygous for both. Interestingly, these two variants were composed similarly, 
differing only by two SNPs. We then expanded the haplotype 20 SNPs to the right and 30 SNPs 
to the left to examine a larger 61 SNP haplotype that ranged from SNP location 218,177,182 to 
218,725,045. There were 206 variants of this extended haplotype found among subjects. Each 
variant was assigned a number 1-206. Of the 206 variants, fifteen were found among five of the 
nuclear families in the study (Figure 6).  
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Figure 4. Association Analysis of RAB3GAP2 (A) and MARK1 (B) regions 
Figure 5. The original RAB3GAP2 haplotype stretch 
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Figure 6. The extended RAB3GAP2 haplotype stretch 
Pedigrees of the five families (Figure 7) display who in each family carries which 
haplotype variant. Black symbols represent family members who are affected by schizophrenia. 
None of the haplotype variants appeared to be consistent with highly penetrant risk alleles for 
schizophrenia. Variant 43 was initially considered as a potential risk variant because it was 
identified in three cases from Family 1 (13881, 20256, 20310), and no controls. This variant is 
very rare in the population, having a frequency of less that 0.03% and only appearing in the three 
individuals from Family 1. However, because of its low frequency and appearance in only this 
one family, it is likely that it is a variant unique to the family and not associated with 
schizophrenia in the Palau population. More evidence would have to be provided to suggest that 
it is related to the disease status of the subjects. 
Variant 134 appears in two subjects from Family 2 as a compound heterozygote with 
variant 118. However, the mother of the family is unaffected and the son is affected despite 
having identical genotypes in that region. This inconsistency allows us to conclude that those 
variants are not associated with disease status in the family.  
Variant 32 is one of the more common haplotypes and appears in approximately 2% of 
the Palauan population. It also appears in two of our families: Family 3 and Family 5. In Family 
3, subject 22420 is affected with schizophrenia and is homozygous for variant 32. His brother, 
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subject 26154 is only heterozygous for the variant. Initially, this hinted that variant 32 may be 
related to schizophrenia when in the homozygous state, following a recessive inheritance pattern. 
However, when variants 32 and 118 are compared based on the SNPs that compose the 
haplotypes, there is very little difference. Only ten of the 61 SNPs are different and there are still 
long stretches within the haplotype where there is consistent SNP sharing. For this reason, there 
is not enough evidence to conclude that homozygosity of variant 32 is the reason for 
schizophrenia expression. In Family 5, two siblings (26165 and 5000) share the same 175/32 
genotype, yet only subject 5000 has positive disease status. This suggests that this particular 
genotype is unrelated to having schizophrenia.  
Variant 54 is also found in 2% of the population, but in only one of the families. The 
affected subject, 22522 is a compound heterozygote for variants 54 and 69. When looking at 
these specific haplotypes, there are several breaks in SNP sharing. Because of this, it is unlikely 
that the subject would be affected by schizophrenia because of homozygosity in this region. 
Without further evidence, it cannot be said that variant 54 a has significant relation to disease 
status.  
Variant 175 is a rare variant with a frequency of 0.08% in the Palauan population. It is 
found in three individuals in Family 5, two of which are affected. However, just as with variant 
32, the two brothers in the family have the same genotype but opposite disease status. This 
suggests that the components of the genotype are not contributing to their schizophrenia status.  
In support of our findings, we coded the 11-SNP and 61-SNP haplotypes into an allele 
format (1 has haplotype of interest, 2 does not have the haplotype) to run MQLS and examine 
haplotype frequencies in cases and controls taking into account relatedness. No significant 
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differences were found between cases and controls for the 11-SNP (p=0.394) and 61-SNP 
haplotype frequencies (p=0.434).  
Figure 7. RAB3GAP2 family pedigrees 
4.2.2 MARK1 Region 
Adjacent to the RAB3GAP2 region that is within the HBD locus on 1q41, there is another 
portion of the locus that is shared among three of the subjects. This includes a 16 SNP sub-
haplotype (218,579,529 bp to 218,906,324 bp). (Figure 4-B). This sub-haplotype falls within the 
MARK1 gene. For this haplotype, we identified 9 cases and 3 controls that were also 
homozygous and yielding an odds ratio of 2.30.  
Although this odds ratio suggested that over twice as many cases would be homozygous 
for this sub-haplotype compared to controls, we wanted to evaluate further whether this locus 
was harboring highly penetrant recessive risk alleles. To investigate this, we looked through all 
variants of the haplotype located at this 16 SNP locus that were carried by cases. There were 51 
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variants of the haplotype identified. Each variant was assigned a number 1-51. Of the 51 
variants, five were found among four of the nuclear families in the study (Figure 8.)  
Figure 8. MARK1 haplotype stretch 
Pedigrees of the four families (Figure 9) display who in each family carries which haplotype 
variant. Variant 27 was suspected to follow a pattern that suggested recessive inheritance in that 
is appears in all four of the families, and every individual who is homozygous for this specific 
haplotype is also affected with schizophrenia. However, it has a population frequency of close to 
17%, so it is not surprising that it is present in all the families. Subjects who carry one copy of 
variant 27 are unaffected. In both Family 3 and Family 4, it appears that both parents are 
unaffected carrier of haplotype 27. Their children then inherited both copies of the haplotype and 
are affected, With this information alone, it was hypothesized that haplotype 27 was a potential 
disease causal variant that followed the rules of a recessive inheritance pattern.  
In order to evaluate this haplotype more closely, the specific SNPs that made up these 
five haplotypes were analyzed and compared (Figure 8). If the hypothesis were to be correct, 
then affected subjects should possess haplotypes with significantly more SNP sharing between 
their two haplotypes than those individuals who are unaffected. Given the composure of the 
haplotypes, this does not seem to be the case. The heterozygous parents in Family 3 and the 
heterozygous father in Family 4 all have the 27/47 genotype and are all unaffected. However, 
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when looking at the difference in the haplotypes between variants 27 and 47, it can be seen that 
they only differ by one SNP. For their genotype to be causative of the disease status, this one 
SNP would have to be the reason, which is highly unlikely. The difference in their haplotypes 
and that of their children is not enough that it should affect whether or not they have 
schizophrenia. In addition, subject 22587 in Family 1 is also affected, yet the SNPs that make up 
variants 26 and 6 differ more than variants 27 and 47, and thus would not be considered to have 
homozygosity in this region.  
In support of our findings, we coded the 16-SNP haplotype into an allele format (1 has 
haplotype of interest, 2 does not have the haplotype) to run MQLS and examine haplotype 
frequencies in cases and controls taking into account relatedness. No significance difference was 
found between cases and controls for the 16-SNP haplotype frequencies (p=0.384).  
Figure 9. MARK1 family pedigrees 
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4.2.3 DISC1 REGION 
Three affected subjects shared a locus HBD on 1q42.2 comprised of 593 SNPs spanning 
227,316,809 bp to 230,388,213 bp (Build HG 18). None of these subjects, however, share a 
substantial portion of their haplotypes. The largest portion of the locus shared among two of the 
subjects is a 33 SNP sub-haplotype (230,223,388 bp to 230,384,737 bp.) (Figure 10).  This sub-
haplotype falls within the DISC1 gene. For this sub-haplotype, we identified 7 cases and 2 
controls who were also homozygous and yielding an odds ratio of 2.67.  
 
Figure 10. Association Analysis of DISC1 region 
 
Similar to the MARK1 region, this odds ratio suggests that this haplotype would be 
homozygous in twice as many cases compared to controls. However, we wanted to evaluate this 
further before concluding that this locus was harboring recessive risk alleles. To investigate this, 
we looked through the variants of the haplotype located at this 33 SNP locus carried by cases. 
 36 
There were 109 different variants of the haplotype identified. Each variant was assigned a 
number 1-109. Three of the 109 variants were found in one of the study’s families. These 
variants were labeled as 85, 31, and 97 (Figure 11).  
Figure 11. DISC 1 haplotype stretch 
The pedigree of the family (Figure 12) display who in the family carries which haplotype variant. 
The limited family history by itself was not able to offer support that these variants were 
significant to disease risk. However, the composure of these haplotypes was analyzed further, 
and a pattern was revealed in a smaller 19 SNP stretch (230,260,242 bp to 230 351, 829 bp; 
highlighted in Figure 11). Variants 85 and 31 were identical in this stretch, making subject 20306 
homozygous in this region. Subject 22354 is homozygous as well since he carries two copies of 
variant 997. Both 20306 and 22354 are affected with schizophrenia. The only unaffected 
individual is subject 22507 who would be considered heterozygous because 31 and 97 are not 
similar haplotype variants. This may be important information; however without a larger number 
of subjects who possess these variants, it cannot be said with confidence this is significant. The 
33-SNP haplotype was coded to run MQLS, and no significant differences were able to be found 
between cases and controls (p=0.785).  
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Figure 12. DISC 1 family pedigree 
 
4.2.4 FAM184A REGION 
Three affected subjects shared a locus HBD on 6q22.31 comprised of 1,553 SNPs spanning 
106,922,247 bp to 124,024,764 bp (Build HG 18). None of these subjects showed sharing in a 
substantial portion of their haplotypes. The largest portion of the locus shared among two of the 
subjects is an 82 SNP sub-haplotype (118,587,907 bp to 119,427,882 bp) (Figure 13). This sub-
haplotype falls within the FAM184A gene. For this sub-haplotype, we identified 7 cases and 1 
control that were also homozygous, yielding an odds ratio of 5.38.  
This odds ratio is large enough to make this region worth of investigating for highly 
penetrant recessive risk alleles. Because of this, we looked through all variants of the haplotype 
located at this 82 SNP locus that were carried by cases, and 151 variants were identified. These 
variants were labeled with numbers 1-151. Five of the 151 variants were found among two of the 
study’s families (Figure 14).  The variants were labeled 2, 136, 65, 146, and 94.  
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Figure 13. Association Analysis of FAM184A region 
Figure 14. FAM184A haplotype stretch 
Pedigrees of the two families (Figure 15) display who in each family carries each 
haplotype variant. Haplotype variant 136 is homozygous in two of the four affected subjects 
(22392 and 20306), and heterozygous in subject 22391. If variant 136 was associated with risk, it 
would be expected that variant 146 would have similar SNP composure to 136 since subject 
22391 is also affected and is a compound heterozygote for haplotypes 146 and 136. This is not the 
case. Subject 22354 is also affected. If homozygosity were important in this region in relation to 
schizophrenia, it would be hypothesized that 65 and 2 would have similar composure among the 
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SNPs as well. Again, this is not the case. Coding the 82-SNP haplotype to an allele format to run 
MQLS supports our findings. No significant differences were found between cases and controls 
(p=0.216).   
Figure 15. FAM184A family pedigrees 
4.2.5 IGSF9B REGION 
Three affected subjects shared a locus HBD on 11q25 comprised of 589 SNPs spanning 
130,376,165 bp to 134,443,679 bp (Build HG 18). Although none of these subjects shared a 
substantial portion of their haplotype, they all shared a 24 SNP sub-haplotype (133,954,456 bp to 
134,090,010 bp) (Figure 16). This sub-haplotype falls within the IGSF9B gene. For this sub-
haplotype, we identified 14 cases and 7 controls that were homozygous, yielding an odds ratio of 
1.53.  
Similar to the RAB3GAP2 region, this odds ratio does not lend much support for highly 
penetrant recessive alleles in this region. We evaluated the possibility that sharing of this 24 SNP 
sub-haplotype could have been due to a risk allele with a different inheritance pattern. As with 
the other regions, we looked through all variants of the haplotype located at this 24 SNP locus 
that were carried by cases, and 45 variants were identified. These variants were labeled with 
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numbers 1-45. Five of the 45 variants were seen among six of the study’s families (Figure 17). 
These variants were labeled 27, 12, 14, 39, and 21.  
Figure 16. Association Analysis of IGSF9B region 
Figure 17. IGSF9B haplotype stretch 
Pedigrees of the six families (Figure 18) display who in each family carries each haplotype 
variant. Variant 27 is present more often in the families than any of the others. However, it does 
not appear to show any association with gene status, given that there are an equal number of 
affected and unaffected individuals who are homozygous for the variant. None of the other 
variants show a pattern through the families that would be consistent with an association with 
schizophrenia risk.  
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To support the findings, we coded the 24-SNP into an allele format to run MQLS. No 
significant differences were found between cases and controls (p=0.514).   
Figure 18. IGSF9B family pedigrees 
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5.0  DISCUSSION 
The heightened prevalence of schizophrenia in the Palau population may be contributed 
to by its genetic history built from a small founder population, series of bottleneck events, and 
geographical isolation. Not surprisingly, extensive regions of homozygosity have been found 
along the genome in the Palauan population. The features of homozygous segments, as described 
in this study, have been investigated in an attempt to determine whether there is an association 
between excess regions of homozygosity and risk for schizophrenia. Specifically, our aim was to 
uncover potential loci that may be harboring highly penetrant recessive risk alleles.  
Through an intricate search of homozygous blocks along the genome, we identified 
regions in which more cases than controls shared HBD segments. These regions overlapped 
several genes that could be associated with psychosis, due to their expression within functional 
parts of the brain. RAB3GAP2, for instance, has been found to play a key role in 
neurodevelopment, with expression specifically in the central nervous system (36). Mutations in 
this gene has also been identified as being the causative of the recessive condition Martsolf 
syndrome (24). Overexpression of the MARK1 gene has been identified  in the prefrontal region 
of postmorten brain tissue in individuals with autism. In addition, overexpression of this gene has 
found to be in association with shortened denderites in animal models (37). DISC1 has 
previously been suggested to have allelic variants associated with schizophrenia in the Finnish 
population, and is believed to regulate multiple aspects of embryonic and adult neurogenesis 
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(25). Although very little is known about the function of the FAM184A gene, microarray 
expression data from the USCS Human Genome Browser has shown it may be expressed in the 
thalamus, medulla oblongata, and fetal brain (34). The IGSF9B gene is believed to have very 
high expression in the brain, specifically the amygdala, corpus callosum, cerebellum, and 
caudate nucleus (35).  However, none of the segments that overlapped in these gene regions 
showed significant association with schizophrenia risk, nor did we identify any locus that likely 
harbors risk alleles. 
Limitations 
 Several limitations may have contributed to the outcome of the results. First, the mating 
relationships and demography of the population is not entirely clear. Although the clans were 
believed to practice exogamy, close relationships may have lead to potential inbreeding that 
could have been influenced by inbreeding depression. Although the mechanism of inbreeding 
depression is not well understood, it is possible it could have had an impact on the data given the 
close relationships of the subjects. In addition, the sample size of the study may not have allowed 
us to see regions that were shared by only a few subjects. Risk alleles may exist throughout the 
population of Palau, but not heavily present in our sample. Finally, it is possible that highly 
penetrant recessive risk variants may not exist in the genome of this population. Reduced 
penetrance and variable expressivity may be playing roles in the expression of schizophrenia and 
related disorders that were inhibiting our identification of recessive risk alleles.   
Future Studies 
The results of our study show that the substantial portion for risk of psychosis in Palau 
can be contributed to neither a common recessive variant, nor a rare, highly penetrant variant. 
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Alternative mechanisms for the association between homozygous segments and risk for 
psychotic disorders may be plausible. For instance, it is possible that the homozygous regions 
contain many variants of modest additive impact on risk, which are joined by chance as a 
haplotype; and homozygosity of that haplotype doubles the risk. Future studies may be able to 
explore alternative inheritance patterns outside of highly penetrant recessive risk variants to 
explain the increased prevalence of schizophrenia with increased homozygosity.  
Conclusions 
Our findings were consistent with previous studies that have reported an increased risk 
for schizophrenia when close mating relationships are practiced, resulting in an increase of HBD 
regions (11, 17). Despite this consistency, we did not find that the homozygous segments in 
Palau trace to the kind of risk loci hypothesized to generate the results of other studies. It is 
possible that the Palau population may be different from other populations examined, or that the 
mechanisms that associate excess regions of homozygosity to risk for schizophrenia is one that is 
not yet understood. Alternative explanations for why increased regions of homozygosity increase 
risk for schizophrenia include the reduction of fitness that is associated with inbreeding (38). In 
addition, studies have shown that an increase risk for schizophrenia is associated with an 
increased number of HBD segments (11). Whatever the explanation, this study illustrates the 
complexity of discovering genes related to complex diseases through homozygosity mapping.   
The complexity of schizophrenia as well as other psychiatric disorders continues to 
impede efforts in solving the genetic puzzle that encodes its development. In working to develop 
the field of psychiatric genetic counseling, it is important to make an attempt in understanding 
the genetics of these neuropsychological illnesses. Identifying causative genes that can 
eventually be tested for can provide new opportunities for patients and their families. A few 
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findings have already begun to bring about discussion of psychiatric illnesses in a clinical 
setting. For example, 25-30% of patients with a 22q11 deletion syndrome (DiGeorge syndrome, 
Velocardiofacial syndrome) have schizophrenic behaviors (19, 44). It is predicted that 0.5-2% of 
all schizophrenia patients may have a deletion of 22q11. If this finding is identified through 
routine chromosome analysis or SNP microarray testing, then a conversation about the 
development of schizophrenic features could take place.  
Any discovery of the molecular etiology related to a diagnosis of schizophrenia could 
impact the health management of a patient. With any genetic condition, concerns regarding 
recurrence risk, family planning, and issues involving stigma are present. Understanding the 
genetics means understanding the inheritance pattern, which gives a better picture of who is at 
risk and whether or not the condition will reoccur in the family. It also provides options for 
reproduction including prenatal genetic diagnosis and preimplantation genetic diagnosis (PGD). 
It also may give patients and families a better sense of control as to how their diagnosis 
happened, and what they can do to better monitor it.  
Continuing efforts to identify risk alleles for schizophrenia is crucial in order for the field 
of psychiatric genetic counseling to grow. All areas of genetic counseling, including prenatal, 
cancer, and pediatrics, began with the discovery of few genetic links to disease, and then 
expanded. Cancer genetics would not be what it is today without the discover of the BRCA 
genes. Diagnosis of Down syndrome would not be as sufficient today had it not been for the 
discovery of the extra 21st chromosome in affected patients. Although this study did not identify 
any risk loci for schizophrenia, the concept of fine-mapping displayed through this project may 
one day uncover region clearly associated with risk, and the foundation of psychiatric genetics 
and counseling can continue to build.   
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APPENDIX A 
RELATIONSHIP MATRICES  
Table 7. Genetic relationship matrix for subjects who are carriers of homozygous haplotypes in RAB3GAP2 
 
 
Table 7. Continued  
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Table 8. Genetic relationship matrix for subjects who are carriers of homozygous haplotypes in MARK1 
Table 9. Genetic relationship matrix for subjects who are carriers of homozygous haplotypes in DISC1 
Table 10. Genetic relationship matrix for subjects who are carriers of homozygous haplotypes in FAM184A 
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Table 11. Genetic relationship matrix for subjects who are carriers of homozygous haplotypes in IGSF9B 
Table 11. Continued 
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APPENDIX B 
IRB APPROVAL FORM 
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